1
|
Cambay F, Forest-Nault C, Dumoulin L, Seguin A, Henry O, Durocher Y, De Crescenzo G. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms. Mol Immunol 2020; 121:144-158. [PMID: 32222585 DOI: 10.1016/j.molimm.2020.03.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 02/26/2020] [Accepted: 03/16/2020] [Indexed: 12/11/2022]
Abstract
Most of therapeutic monoclonal antibodies belong to the immunoglobulin G1 (IgG1) family; they interact with the Fcγ receptors (FcγRs) at the surface of immune cells to trigger effector functions. The IgG1-Fc N-glycans impact the interaction with FcγRs and are considered a critical quality attribute. Pioneer studies on FcγR N-glycans have unveiled an additional complexity in that the N-glycan linked on the Asn-162 of FcγRIIIa was shown to be directly involved in the strong affinity for afucosylated IgG1. The last few years have thus seen the emergence of many studies investigating the complex influence of FcγRIIIa N-glycans on the interaction with IgG1 through their glycosylation sites or their glycoprofiles. In this context, we performed site-directed mutagenesis along with glycoengineering on FcγRs (FcγRI, FcγRIIaH131/b and FcγRIIIaV158/F158) in an effort to elucidate the impact of FcγRs N-glycans on the interaction with IgG1. Furthermore, we assessed their binding to various trastuzumab glycoforms with an enhanced surface plasmon resonance assay. The FcγRIIIa N-glycans had the highest impact on the interaction with IgG1. More specifically, the N162 glycan positively influenced the affinity (15-fold) for afucosylated IgG1 while the N45 glycan presented a negative impact (2-fold) regardless of the IgG1 glycoforms. Interestingly, only the FcγRIIIa glycoprofile had an impact on the interaction with IgG1 with a 1.5-fold affinity increase when FcγRIIIa displays high-mannose glycans. These results provide invaluable insights into the complex and strong influence of N-glycosylation upon FcγRs/IgG1 binding and are instrumental to further understand the impact of FcγRs N-glycosylation in their natural forms.
Collapse
Affiliation(s)
- Florian Cambay
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Canada; Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada
| | - Catherine Forest-Nault
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Canada; Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada
| | - Lea Dumoulin
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Canada
| | - Alexis Seguin
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Canada
| | - Olivier Henry
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Canada.
| | | |
Collapse
|
2
|
Cambay F, Henry O, Durocher Y, De Crescenzo G. Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions. MAbs 2019; 11:435-452. [PMID: 30822189 DOI: 10.1080/19420862.2019.1581017] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The N-glycosylation profile of immunoglobulin G (IgG) is considered a critical quality attribute due to its impact on IgG-Fc gamma receptor (FcγR) interactions, which subsequently affect antibody-dependent cell-based immune responses. In this study, we investigated the impact of the FcγR capture method, as well as FcγR N-glycosylation, on the kinetics of interaction with various glycoforms of trastuzumab (TZM) in a surface plasmon resonance (SPR) biosensor assay. More specifically, we developed a novel strategy based on coiled-coil interactions for the stable and oriented capture of coil-tagged FcγRs at the biosensor surface. Coil-tagged FcγR capture outperformed all other capture strategies applied to the SPR study of IgG-FcγR interactions, as the robustness and reproducibility of the assay and the shelf life of the biosensor chip were excellent (> 1,000 IgG injections with the same biosensor surface). Coil-tagged FcγRs displaying different N-glycosylation profiles were generated either by different expression systems, in vitro glycoengineering or by size-exclusion chromatography, and roughly characterized by lectin blotting. Of salient interest, the overlay of their kinetics of interaction with several TZM glycoforms revealed key differences on both association and dissociation kinetics, confirming a complex influence of the FcγR N-glycosylation and its inherent heterogeneity upon receptor interaction with mAbs. This work is thus an important step towards better understanding of the impact of glycosylation upon binding of IgGs, either natural or engineered, to their receptors.
Collapse
Affiliation(s)
- Florian Cambay
- a Department of Chemical Engineering , Polytechnique Montréal , Montréal , Québec , Canada.,b Human Health Therapeutics Research Center , National Research Council Canada , Montréal , Québec , Canada
| | - Olivier Henry
- a Department of Chemical Engineering , Polytechnique Montréal , Montréal , Québec , Canada
| | - Yves Durocher
- b Human Health Therapeutics Research Center , National Research Council Canada , Montréal , Québec , Canada.,c Département de Biochimie et Médecine Moléculaire , Université de Montréal , Montréal , Québec , Canada
| | - Gregory De Crescenzo
- a Department of Chemical Engineering , Polytechnique Montréal , Montréal , Québec , Canada
| |
Collapse
|
3
|
Yang D, Kroe-Barrett R, Singh S, Roberts CJ, Laue TM. IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development. MAbs 2017; 9:1231-1252. [PMID: 28812955 PMCID: PMC5680800 DOI: 10.1080/19420862.2017.1367074] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
A central dogma in immunology is that an antibody's in vivo functionality is mediated by 2 independent events: antigen binding by the variable (V) region, followed by effector activation by the constant (C) region. However, this view has recently been challenged by reports suggesting allostery exists between the 2 regions, triggered by conformational changes or configurational differences. The possibility of allosteric signals propagating through the IgG domains complicates our understanding of the antibody structure-function relationship, and challenges the current subclass selection process in therapeutic antibody design. Here we review the types of cooperativity in IgG molecules by examining evidence for and against allosteric cooperativity in both Fab and Fc domains and the characteristics of associative cooperativity in effector system activation. We investigate the origin and the mechanism of allostery with an emphasis on the C-region-mediated effects on both V and C region interactions, and discuss its implications in biological functions. While available research does not support the existence of antigen-induced conformational allosteric cooperativity in IgGs, there is substantial evidence for configurational allostery due to glycosylation and sequence variations.
Collapse
Affiliation(s)
- Danlin Yang
- a Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield , Connecticut , USA
| | - Rachel Kroe-Barrett
- a Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc. , Ridgefield , Connecticut , USA
| | - Sanjaya Singh
- b Janssen BioTherapeutics, Janssen Research & Development, LLC, Spring House , Pennsylvania , USA
| | - Christopher J Roberts
- c Department of Chemical and Biomolecular Engineering , University of Delaware , Newark , Delaware , USA
| | - Thomas M Laue
- d Department of Molecular, Cellular, and Biomedical Sciences , University of New Hampshire , Durham , New Hampshire , USA
| |
Collapse
|
4
|
O'Kennedy R, Fitzgerald S, Murphy C. Don't blame it all on antibodies – The need for exhaustive characterisation, appropriate handling, and addressing the issues that affect specificity. Trends Analyt Chem 2017. [DOI: 10.1016/j.trac.2017.01.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
5
|
Antibodies - Nature's analytical masterpieces. Methods 2017; 116:1-3. [PMID: 28351694 DOI: 10.1016/j.ymeth.2017.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
6
|
Computational tools for epitope vaccine design and evaluation. Curr Opin Virol 2015; 11:103-12. [PMID: 25837467 DOI: 10.1016/j.coviro.2015.03.013] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2014] [Revised: 03/13/2015] [Accepted: 03/16/2015] [Indexed: 12/15/2022]
Abstract
Rational approaches will be required to develop universal vaccines for viral pathogens such as human immunodeficiency virus, hepatitis C virus, and influenza, for which empirical approaches have failed. The main objective of a rational vaccine strategy is to design novel immunogens that are capable of inducing long-term protective immunity. In practice, this requires structure-based engineering of the target neutralizing epitopes and a quantitative readout of vaccine-induced immune responses. Therefore, computational tools that can facilitate these two areas have played increasingly important roles in rational vaccine design in recent years. Here we review the computational techniques developed for protein structure prediction and antibody repertoire analysis, and demonstrate how they can be applied to the design and evaluation of epitope vaccines.
Collapse
|
7
|
Borisov OV, Alvarez M, Carroll JA, Brown PW. Sequence Variants and Sequence Variant Analysis in Biotherapeutic Proteins. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Oleg V. Borisov
- Novavax, Inc., Gaithersburg, Maryland 20878, United States
- Roche Group Member, Genentech, Inc., South San Francisco, California 94080, United States
- Pfizer Worldwide Research & Development, Chesterfield, Missouri 63017, United States
| | - Melissa Alvarez
- Novavax, Inc., Gaithersburg, Maryland 20878, United States
- Roche Group Member, Genentech, Inc., South San Francisco, California 94080, United States
- Pfizer Worldwide Research & Development, Chesterfield, Missouri 63017, United States
| | - James A. Carroll
- Novavax, Inc., Gaithersburg, Maryland 20878, United States
- Roche Group Member, Genentech, Inc., South San Francisco, California 94080, United States
- Pfizer Worldwide Research & Development, Chesterfield, Missouri 63017, United States
| | - Paul W. Brown
- Novavax, Inc., Gaithersburg, Maryland 20878, United States
- Roche Group Member, Genentech, Inc., South San Francisco, California 94080, United States
- Pfizer Worldwide Research & Development, Chesterfield, Missouri 63017, United States
| |
Collapse
|
8
|
Yang Y, Wang G, Huang X, Du Z. Crystallographic and modelling studies suggest that the SKICH domains from different protein families share a common Ig-like fold but harbour substantial structural variations. J Biomol Struct Dyn 2014; 33:1385-98. [PMID: 25187058 DOI: 10.1080/07391102.2014.951688] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
TAX1BP1 is a pleiotropic multi-domain protein involved in many important biological processes such as signal transduction, cell growth and apoptosis, transcriptional coactivation, membrane trafficking, neurotransmission and autophagy. The N-terminus of TAX1BP1 contains a SKICH domain implicated in autophagy. SKICH domains are also present in four other proteins including NDP52, CALCOCO1, SKIP and PIPP. The SKICH domains of SKIP and PIPP mediate plasma membrane localisation. The functions of the SKICH domains of NDP52 and CALCOCO1 are not known. Here we report the crystal structure of the TAX1BP1 SKICH domain, which has an Ig-like fold similar to the NDP52 SKICH domain. Extensive pairwise and clustered aromatic π-stacking interactions are present in the TAX1BP1 SKICH domain. The aromatic residues mediating these interactions can be classified into four groups with varying degrees of conservation among different protein families. The interactions mediated by highly conserved residues are found in the interior and one outward face of the Ig-like β-barrel, representing common structural features of the SKICH domains. Three TAX1BP1-specific pairwise interactions locate in the loop regions, each augmented by a proline-aromatic interaction. The three proline-aromatic clusters are linked together by more generic hydrophobic interactions, forming a unique hydrophobic surface at one end of the TAX1BP1 SKICH domain. The structures and homologous models of SKICH domains from different proteins reveal substantial differences in electrostatic surface properties of the domains. Together with existing biochemical data, results from the structural study suggest that an intact SKICH domain is required for the autophagy function of TAX1BP1.
Collapse
Affiliation(s)
- Yang Yang
- a Department of Chemistry and Biochemistry , Southern Illinois University , Carbondale 62901 , IL , USA
| | | | | | | |
Collapse
|
9
|
Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, Volkin DB. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J Pharm Sci 2013; 102:3942-56. [PMID: 24114789 DOI: 10.1002/jps.23730] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2013] [Revised: 08/20/2013] [Accepted: 08/29/2013] [Indexed: 12/29/2022]
Abstract
The structural integrity and conformational stability of an IgG1 monoclonal antibody (mAb), after partial or complete enzymatic removal of the N-linked Fc glycan, were compared with the untreated mAb over a wide range of temperature (10°C-90°C) and solution pH (3-8) using circular dichroism, fluorescence spectroscopy, and static light scattering combined with data visualization employing empirical phase diagrams. Subtle-to-larger stability differences between the different glycoforms were observed. Improved detection of physical stability differences was then demonstrated over narrower pH range (4.0-6.0) using smaller temperature increments, especially when combined with an alternative data visualization method (radar plots). Differential scanning calorimetry and differential scanning fluorimetry were then utilized and also showed an improved ability to detect differences in the physical stability of a mAb glycoform. On the basis of these results, a two-step methodology was used in which conformational stability of a mAb glycoform is first screened with a wide variety of instruments and environmental stresses, followed by a second evaluation with optimally sensitive experimental conditions, analytical techniques, and data visualization methods. With this approach, a high-throughput biophysical analysis to assess relatively subtle conformational stability differences in protein glycoforms is demonstrated.
Collapse
Affiliation(s)
- Mohammad A Alsenaidy
- Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas, 66047
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Shaheen HH, Prinz B, Chen MT, Pavoor T, Lin S, Houston-Cummings NR, Moore R, Stadheim TA, Zha D. A dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastoris. PLoS One 2013; 8:e70190. [PMID: 23875020 PMCID: PMC3707868 DOI: 10.1371/journal.pone.0070190] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2013] [Accepted: 06/14/2013] [Indexed: 11/22/2022] Open
Abstract
State-of-the-art monoclonal antibody (mAb) discovery methods that utilize surface display techniques in prokaryotic and eukaryotic cells require multiple steps of reformatting and switching of hosts to transition from display to expression. This results in a separation between antibody affinity maturation and full-length mAb production platforms. Here, we report for the first time, a method in Glyco-engineered Pichiapastoris that enables simultaneous surface display and secretion of full-length mAb molecules with human-like N-glycans using the same yeast cell. This paradigm takes advantage of homo-dimerization of the Fc portion of an IgG molecule to a surface-anchored "bait" Fc, which results in targeting functional “half” IgGs to the cell wall of Pichiapastoris without interfering with the secretion of full length mAb. We show the utility of this method in isolating high affinity, well-expressed anti-PCSK9 leads from a designed library that was created by mating yeasts containing either light chain or heavy chain IgG libraries. Coupled with Glyco-engineered Pichiapastoris, this method provides a powerful tool for the discovery and production of therapeutic human mAbs in the same host thus improving drug developability and potentially shortening the discovery time cycle.
Collapse
Affiliation(s)
- Hussam H. Shaheen
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
- * E-mail: (HS); (DZ)
| | - Bianka Prinz
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Ming-Tang Chen
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Tej Pavoor
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Song Lin
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Nga Rewa Houston-Cummings
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Renee Moore
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Terrance A. Stadheim
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
| | - Dongxing Zha
- GlycoFi, Biologics Discovery, Merck Research Laboratories, Merck & Co., Inc., Lebanon, New Hampshire, United States of America
- * E-mail: (HS); (DZ)
| |
Collapse
|
11
|
Baschieri S. Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates. INNOVATION IN VACCINOLOGY 2012. [PMCID: PMC7122206 DOI: 10.1007/978-94-007-4543-8_3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Traditional vaccines such as inactivated or live attenuated vaccines, are gradually giving way to more biochemically defined vaccines that are most often based on a recombinant antigen known to possess neutralizing epitopes. Such vaccines can offer improvements in speed, safety and manufacturing process but an inevitable consequence of their high degree of purification is that immunogenicity is reduced through the lack of the innate triggering molecules present in more complex preparations. Targeting recombinant vaccines to antigen presenting cells (APCs) such as dendritic cells however can improve immunogenicity by ensuring that antigen processing is as efficient as possible. Immune complexes, one of a number of routes of APC targeting, are mimicked by a recombinant approach, crystallizable fragment (Fc) fusion proteins, in which the target immunogen is linked directly to an antibody effector domain capable of interaction with receptors, FcR, on the APC cell surface. A number of virus Fc fusion proteins have been expressed in insect cells using the baculovirus expression system and shown to be efficiently produced and purified. Their use for immunization next to non-Fc tagged equivalents shows that they are powerfully immunogenic in the absence of added adjuvant and that immune stimulation is the result of the Fc-FcR interaction.
Collapse
Affiliation(s)
- Selene Baschieri
- Italian National Agency for New Technolo, Energy and Sustainable Economic Developm, ENEA, Via Anguillarese 301, Rome, 00123 Italy
| |
Collapse
|